171 related articles for article (PubMed ID: 17967134)
1. Risedronate reduces osteoclast precursors and cytokine production in postmenopausal osteoporotic women.
D'Amelio P; Grimaldi A; Di Bella S; Tamone C; Brianza SZ; Ravazzoli MG; Bernabei P; Cristofaro MA; Pescarmona GP; Isaia G
J Bone Miner Res; 2008 Mar; 23(3):373-9. PubMed ID: 17967134
[TBL] [Abstract][Full Text] [Related]
2. Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: a randomized, controlled trial.
Anastasilakis AD; Goulis DG; Polyzos SA; Gerou S; Koukoulis G; Kita M; Avramidis A
Horm Metab Res; 2008 Apr; 40(4):281-5. PubMed ID: 18275008
[TBL] [Abstract][Full Text] [Related]
3. Spontaneous osteoclast formation from peripheral blood mononuclear cells in postmenopausal osteoporosis.
D'Amelio P; Grimaldi A; Pescarmona GP; Tamone C; Roato I; Isaia G
FASEB J; 2005 Mar; 19(3):410-2. PubMed ID: 15611151
[TBL] [Abstract][Full Text] [Related]
4. The effect of risedronate treatment on serum osteoprotegerin and bone marker levels in postmenopausal women with osteoporosis.
Karadag-Saygi E; Akyuz G; Bizargity P; Ay P
Gynecol Endocrinol; 2011 Dec; 27(12):1033-6. PubMed ID: 21627558
[TBL] [Abstract][Full Text] [Related]
5. Alendronate reduces osteoclast precursors in osteoporosis.
D'Amelio P; Grimaldi A; Cristofaro MA; Ravazzoli M; Molinatti PA; Pescarmona GP; Isaia GC
Osteoporos Int; 2010 Oct; 21(10):1741-50. PubMed ID: 19949772
[TBL] [Abstract][Full Text] [Related]
6. Dual modulation of osteoclast differentiation by lipopolysaccharide.
Zou W; Bar-Shavit Z
J Bone Miner Res; 2002 Jul; 17(7):1211-8. PubMed ID: 12096834
[TBL] [Abstract][Full Text] [Related]
7. Effects of 3- and 5-year treatment with risedronate on bone mineralization density distribution in triple biopsies of the iliac crest in postmenopausal women.
Zoehrer R; Roschger P; Paschalis EP; Hofstaetter JG; Durchschlag E; Fratzl P; Phipps R; Klaushofer K
J Bone Miner Res; 2006 Jul; 21(7):1106-12. PubMed ID: 16813531
[TBL] [Abstract][Full Text] [Related]
8. Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions.
Quinn JM; Itoh K; Udagawa N; Hausler K; Yasuda H; Shima N; Mizuno A; Higashio K; Takahashi N; Suda T; Martin TJ; Gillespie MT
J Bone Miner Res; 2001 Oct; 16(10):1787-94. PubMed ID: 11585342
[TBL] [Abstract][Full Text] [Related]
9. Risedronate inhibits bone marrow mesenchymal stem cell adipogenesis and switches RANKL/OPG ratio to impair osteoclast differentiation.
Jin J; Wang L; Wang XK; Lai PL; Huang MJ; Jin DD; Zhong ZM; Chen JT; Bai XC
J Surg Res; 2013 Mar; 180(1):e21-9. PubMed ID: 22487394
[TBL] [Abstract][Full Text] [Related]
10. The effect of risedronate treatment on serum cytokines in postmenopausal osteoporosis: a 6-month randomized and controlled study.
Dundar U; Kavuncu V; Ciftci IH; Evcik D; Solak O; Cakir T
J Bone Miner Metab; 2009; 27(4):464-70. PubMed ID: 19301089
[TBL] [Abstract][Full Text] [Related]
11. Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate.
Durchschlag E; Paschalis EP; Zoehrer R; Roschger P; Fratzl P; Recker R; Phipps R; Klaushofer K
J Bone Miner Res; 2006 Oct; 21(10):1581-90. PubMed ID: 16995813
[TBL] [Abstract][Full Text] [Related]
12. Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: comparison with IL1 beta and tumour necrosis factor alpha.
Dai SM; Nishioka K; Yudoh K
Ann Rheum Dis; 2004 Nov; 63(11):1379-86. PubMed ID: 15479886
[TBL] [Abstract][Full Text] [Related]
13. Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume.
Fratzl P; Roschger P; Fratzl-Zelman N; Paschalis EP; Phipps R; Klaushofer K
Calcif Tissue Int; 2007 Aug; 81(2):73-80. PubMed ID: 17612779
[TBL] [Abstract][Full Text] [Related]
14. Two distinct cellular mechanisms of osteoclast formation and bone resorption in periprosthetic osteolysis.
Sabokbar A; Kudo O; Athanasou NA
J Orthop Res; 2003 Jan; 21(1):73-80. PubMed ID: 12507582
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials.
Miller PD; Roux C; Boonen S; Barton IP; Dunlap LE; Burgio DE
J Bone Miner Res; 2005 Dec; 20(12):2105-15. PubMed ID: 16294264
[TBL] [Abstract][Full Text] [Related]
16. Human trabecular bone-derived osteoblasts support human osteoclast formation in vitro in a defined, serum-free medium.
Atkins GJ; Kostakis P; Welldon KJ; Vincent C; Findlay DM; Zannettino AC
J Cell Physiol; 2005 Jun; 203(3):573-82. PubMed ID: 15573398
[TBL] [Abstract][Full Text] [Related]
17. Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors.
Shalhoub V; Faust J; Boyle WJ; Dunstan CR; Kelley M; Kaufman S; Scully S; Van G; Lacey DL
J Cell Biochem; 1999 Feb; 72(2):251-61. PubMed ID: 10022507
[TBL] [Abstract][Full Text] [Related]
18. Osteoclast inhibitory effects of vitamin K2 alone or in combination with etidronate or risedronate in patients with rheumatoid arthritis: 2-year results.
Morishita M; Nagashima M; Wauke K; Takahashi H; Takenouchi K
J Rheumatol; 2008 Mar; 35(3):407-13. PubMed ID: 18260178
[TBL] [Abstract][Full Text] [Related]
19. LIGHT (TNFSF14), a novel mediator of bone resorption, is elevated in rheumatoid arthritis.
Edwards JR; Sun SG; Locklin R; Shipman CM; Adamopoulos IE; Athanasou NA; Sabokbar A
Arthritis Rheum; 2006 May; 54(5):1451-62. PubMed ID: 16649193
[TBL] [Abstract][Full Text] [Related]
20. Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway.
Luo XH; Guo LJ; Xie H; Yuan LQ; Wu XP; Zhou HD; Liao EY
J Bone Miner Res; 2006 Oct; 21(10):1648-56. PubMed ID: 16995820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
